Anavex Life Sciences Corp (AVXL)

[tradeherpete]

tradeherpete
Re: None
Friday, December 22, 2023 7:24:38 AM
Post# of 447316
Someone just paid 14b for a company offering a Muscarinic Receptor Agonist.

That receptor is in the Blarcamesine bag of tricks. How much is it worth when coupled with the S-1R receptor?

All Content and Data provided by Third-Parties — Terms of Use
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
BUSINESS WIRE 7:05 AM ET 12/22/2023
Symbol Last Price Change
BMY 51.26down 0 (0%)
KRTX 215.19down 0 (0%)
QUOTES AS OF 04:10:00 PM ET 12/21/2023

Transaction Delivers KarXT, a First-in-Class M1 / M4 Muscarinic Receptor Agonist, with Differentiated Efficacy and Safety

KarXT Is a Potential First-in-Class Treatment for Schizophrenia and as an Adjunctive Therapy, and First-in-Disease Treatment for Alzheimer’s Disease Psychosis, with Promise in Additional Neuropsychiatric and Neurodegenerative Indications

KarXT Is Expected to Launch in the U.S. for the Treatment of Schizophrenia in Adults with a Prescription Drug User Fee Act Date of September 26, 2024

Bristol Myers Squibb (BMY) to Host a Conference Call Today at 8:00 a.m. ET

PRINCETON, N.J. & BOSTON--(BUSINESS WIRE)-- Bristol Myers Squibb(BMY) and Karuna Therapeutics, Inc.(KRTX) (“Karuna”) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb(BMY) has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired. The transaction was unanimously approved by both the Bristol Myers Squibb(BMY) and Karuna Boards of Directors.